TTY Biopharm Company Stock Forecast for 2023 - 2025 - 2030
Updated on 03/28/2024
TTY Biopharm Company Stock Forecast and Price Target
Given the average yearlong price target of NT$86.50 provided by prominent analysts over the past few months, there is a potential upside of approximately 7.05% from the last closing price in March, 2024 for TTY Biopharm Company's stock if it is reached. This estimation is based on a high estimate of NT$95.00 and a low estimate of NT$78.00. Even if you are not interested in 4105 stock, it is still crucial to be aware of its competitors.
7.05% Upside
TTY Biopharm Company Fair Value Forecast for 2023 - 2025 - 2030
In the last four years, TTY Biopharm Company's Price has decreased from NT$71.45 to NT$0.00 – a 100.00% drop! For next year, the 2 analysts predict Fair Value of NT$110.17, which would mean an increase of 100.00%. Over the next seven years, the pros' prediction is Fair Valueof NT$115.17, which would mean a seven-year growth forecast of 100.00%.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
JNJ Stock Forecast | Johnson & Johnson | Outperform |
9
|
$161.23 | Buy/Sell | $174.55 | 5.44% |
ABT Stock Forecast | Abbott Laboratories | Outperform |
9
|
$120.19 | Buy/Sell | $118.92 | 4.83% |
AZN Stock Forecast | AstraZeneca PLC | Outperform |
17
|
£104.50 | Buy/Sell | £165.99 | 53.79% |
NOVN Stock Forecast | Novartis | Outperform |
10
|
CHF88.80 | Buy/Sell | CHF105.00 | 23.95% |
PFE Stock Forecast | Pfizer | Outperform |
2
|
$28.37 | Buy/Sell | $32.87 | 10.82% |
TTY Biopharm Company Revenue Forecast for 2023 - 2025 - 2030
In the last two years, TTY Biopharm Company's Revenue has grown, increasing from NT$4.22B to NT$5.06B – an increase of 19.89%. For next year, the 2 analysts predict Revenue of NT$5.74B, which would mean an increase of 13.45%. Over the next seven years, the pros' prediction is Revenueof NT$5.77B, which would mean a seven-year growth forecast of 13.91%.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
SAN Stock Forecast | Sanofi | Outperform |
16
|
88.32€ | Buy/Sell | 102.80€ | 21.15% |
CSL Stock Forecast | CSL | Outperform |
12
|
$281.20 | Buy/Sell | $205.51 | -27.94% |
GSK Stock Forecast | GSK | Outperform |
12
|
£16.75 | Buy/Sell | £17.30 | 11.04% |
TTY Biopharm Company Dividend per Share Forecast for 2023 - 2025 - 2030
In the last two years, TTY Biopharm Company has seen a decline in its Dividend per Share, from NT$4.00 to NT$3.40 – a 15.00% decrease. In the next year, analysts expect Dividend per Share to reach NT$4.10 – an increase of 20.59%. For the next seven years, the forecast is for Dividend per Share to grow by 13.62%.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
BAX Stock Forecast | Baxter International Inc | Outperform |
17
|
$43.48 | Buy/Sell | $44.86 | 3.50% |
1093 Stock Forecast | CSPC Pharmaceutical Group | Outperform |
18
|
HK$6.01 | Buy/Sell | HK$9.50 | 54.24% |
4142 Stock Forecast | Adimmune | - |
10
|
NT$31.05 | Buy/Sell | NT$55.00 | -100.00% |
TTY Biopharm Company EBITDA Forecast for 2023 - 2025 - 2030
In the last two years, TTY Biopharm Company's EBITDA has grown by 26.76%, from NT$1.11B to NT$1.41B. For the next year, analysts are expecting EBITDA to reach NT$1.87B – an increase of 32.89%. Over the next seven years, experts predict that EBITDA will grow by 27.49%.
TTY Biopharm Company EBIT Forecast for 2023 - 2025 - 2030
In the last two years, TTY Biopharm Company's EBIT has grown from NT$957.38M to NT$1.23B – a 28.26% increase. Next year, analysts are expecting EBIT to reach NT$1.62B – an increase of 31.52%. Over the next seven years, the forecast is for EBIT to grow by 35.04%.
TTY Biopharm Company EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last four years, TTY Biopharm Company's EPS has decreased from NT$3.71 to NT$0.00 – a 100.00% drop! For next year, the 2 analysts predict EPS of NT$5.72, which would mean an increase of 100.00%. Over the next seven years, the pros' prediction is EPSof NT$5.98, which would mean a seven-year growth forecast of 100.00%.